ArticleJournal of market access & health policy2017
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.
Article in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.Advances in therapy · 2023Pooled it
- A systematic review of moral reasons on orphan drug reimbursement.Orphanet journal of rare diseases · 2021Pooled it
- A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.Frontiers in public health · 2019Pooled it
- Determinants of the Financial Impact of Orphan Drugs in Italy: Differences Between Expected and Observed Pharmaceutical Expenditure.Drugs - real world outcomes · 2025Article
- Development of an multicriteria decision analysis framework for rare disease reimbursement prioritization in Malaysia.International journal of technology assessment in health care · 2024Article
- Defining 'therapeutic value' of medicines: a scoping review.BMJ open · 2023Article
- Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.International journal of environmental research and public health · 2023Review
- Moving beyond the Court of Public Opinion: A Citizens' Jury Exploring the Public's Values around Funding Decisions for Ultra-Orphan Drugs.International journal of environmental research and public health · 2022Article
- The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.Orphanet journal of rare diseases · 2022Article
- Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.Orphanet journal of rare diseases · 2022Article
- Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?Orphanet journal of rare diseases · 2022Review
- Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.Healthcare (Basel, Switzerland) · 2021Article
- Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy.Frontiers in medical technology · 2021Review
- Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome.PharmacoEconomics · 2020Article
- Health economic evaluation of gene replacement therapies: methodological issues and recommendations.Journal of market access & health policy · 2020Article
- Determinants of Orphan Drug Prices in Germany.PharmacoEconomics · 2020Article
- Patient access to orphan drugs in France.Orphanet journal of rare diseases · 2019Article
- Non-profit drug research and development: the case study of Genethon.Journal of market access & health policy · 2019Article
- Unhealthy eating habits around sleep and sleep duration: To eat or fast?World journal of diabetes · 2018Article
- Non-profit Drug Research and Development at a Crossroads.Pharmaceutical research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.